Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

KA Phillips, RL Milne, MA Rookus, MB Daly… - Journal of clinical …, 2013 - ascopubs.org
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …
被引用次数：229 相关文章

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

KA Phillips, RL Milne, MA Rookus, MB Daly… - Journal of Clinical …, 2013 - lup.lub.lu.se
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. |
Lund University Publications Skip to main content LUND UNIVERSITY | LUND UNIVERSITY …

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

KA Phillips, RL Milne, MA Rookus, MB Daly… - Journal of Clinical …, 2013 - europepmc.org
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …
[PDF] researchgate.net

[PDF][PDF] Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

MD Phillips, V A'Beckett St - Clinical Oncology, 2011 - researchgate.net
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Page 1 Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation …

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

KA Phillips, RL Milne… - Journal of …, 2013 - scholarlypublications …
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation
Carriers | Scholarly Publications Skip to main content Universiteit Leiden Leiden University …
[PDF] eur.nl

[PDF][PDF] Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

MD Phillips, V A'Beckett St - Clinical Oncology, 2011 - pure.eur.nl
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Page 1 Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation …
[HTML] nih.gov

[HTML][HTML] Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

KA Phillips, RL Milne, MA Rookus… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KA Phillips, R Milne, M Rookus, M Daly… - Journal of Clinical …, 2013 - repub.eur.nl
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KA Phillips, RL Milne, MA Rookus… - Journal of clinical …, 2013 - pubmed.ncbi.nlm.nih.gov
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KA Phillips, RL Milne, MA Rookus… - Journal of clinical …, 2013 - research.regionh.dk
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers —
The Capital Region of Denmark's Research Portal Skip to main navigation Skip to search …